Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01176474 · ClinicalTrials.gov registry record · Phase 1
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT01176474 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 73 participants.
The verdict
NCT01176474, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to test the side effects of an investigational vaccine with an immune booster, or 2 different boosters together. Investigators also want to find out its effects on the immune system and whether it will decrease the chance that melanoma will return.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- BIOLOGICAL NY-ESO-1 157-165 (165V)
- BIOLOGICAL gp100:280-288 (288V)
- DRUG Montanide ISA 51 vegetable grade (VG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2010-08-13 |
| Est. Completion | 2023-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01176474
The ClinicalTrials.gov registry entry for NCT01176474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT01176474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01176474 about?
NCT01176474 is a clinical study titled "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma". The purpose of this study is to test the side effects of an investigational vaccine with an immune booster, or 2 different boosters together. Investigators also want to find out its effects on the immune system and whether it will decrease the chance that melanoma will return.
What is the current status of trial NCT01176474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2010-08-13. Estimated completion is 2023-01-06.
What interventions are being tested in trial NCT01176474?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), NY-ESO-1 157-165 (165V) (BIOLOGICAL), gp100:280-288 (288V) (BIOLOGICAL), Montanide ISA 51 vegetable grade (VG) (DRUG).
Who is sponsoring clinical trial NCT01176474?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.